Limits...
Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines.

Takeshima M, Ono M, Higuchi T, Chen C, Hara T, Nakano S - Cancer Sci. (2014)

Bottom Line: Lycopene treatment for 168 consecutive hours exhibited a time-dependent and dose-dependent anti-proliferative activity against these cell lines by arresting the cell cycle at the G0 /G1 phase at physiologically achievable concentrations found in human plasma.The greatest growth inhibition was observed in MDA-MB-468 where the sub-G0 /G1 apoptotic population was significantly increased, with demonstrable cleavage of PARP.Taken together, these data indicate that the predominant anticancer activity of lycopene in MDA-MB-468 cells suggests a potential role of lycopene for the prevention of triple negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan.

Show MeSH

Related in: MedlinePlus

Survival curves for lycopene against MCF-7 (○), SK-BR-3 (□) and MDA-MB-468 (△) cells. Cells were treated with various concentrations of lycopene for 168 h and assessed for viability by WST-1 assay, as described in the Materials and Methods. The data represent the means from three independent experiments. Bars, standard deviation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317951&req=5

fig01: Survival curves for lycopene against MCF-7 (○), SK-BR-3 (□) and MDA-MB-468 (△) cells. Cells were treated with various concentrations of lycopene for 168 h and assessed for viability by WST-1 assay, as described in the Materials and Methods. The data represent the means from three independent experiments. Bars, standard deviation.

Mentions: Lycopene treatment for 168 consecutive hours exhibited dose-dependent growth inhibitory activities against MCF-7, SK-BR-3 and MDA-MB-468 cells, with the greatest growth inhibition observed in MDA-MB-468 (Fig.1). MDA-MB-468 cells treated with lycopene for 168 h showed significantly lower IC50 value (10.3 μM), compared to MCF-7 cells (29.9 μM) and SK-BR-3 (22.8 μM), being threefold more sensitive to lycopene than MCF-7 cells (Table1). HER2-positive cells were moderately sensitive to lycopene, showing the IC50 between those of triple-negative and hormone-receptor positive cells. When the exposure time was shortened, IC50 values increased and there were no significant differences of lycopene sensitivity between these cell lines at 72-h exposure (Table1). These data indicate that a relatively long time (more than 72 h) would be required for lycopene to exhibit its true anti-proliferative activity for individual cell lines.


Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines.

Takeshima M, Ono M, Higuchi T, Chen C, Hara T, Nakano S - Cancer Sci. (2014)

Survival curves for lycopene against MCF-7 (○), SK-BR-3 (□) and MDA-MB-468 (△) cells. Cells were treated with various concentrations of lycopene for 168 h and assessed for viability by WST-1 assay, as described in the Materials and Methods. The data represent the means from three independent experiments. Bars, standard deviation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317951&req=5

fig01: Survival curves for lycopene against MCF-7 (○), SK-BR-3 (□) and MDA-MB-468 (△) cells. Cells were treated with various concentrations of lycopene for 168 h and assessed for viability by WST-1 assay, as described in the Materials and Methods. The data represent the means from three independent experiments. Bars, standard deviation.
Mentions: Lycopene treatment for 168 consecutive hours exhibited dose-dependent growth inhibitory activities against MCF-7, SK-BR-3 and MDA-MB-468 cells, with the greatest growth inhibition observed in MDA-MB-468 (Fig.1). MDA-MB-468 cells treated with lycopene for 168 h showed significantly lower IC50 value (10.3 μM), compared to MCF-7 cells (29.9 μM) and SK-BR-3 (22.8 μM), being threefold more sensitive to lycopene than MCF-7 cells (Table1). HER2-positive cells were moderately sensitive to lycopene, showing the IC50 between those of triple-negative and hormone-receptor positive cells. When the exposure time was shortened, IC50 values increased and there were no significant differences of lycopene sensitivity between these cell lines at 72-h exposure (Table1). These data indicate that a relatively long time (more than 72 h) would be required for lycopene to exhibit its true anti-proliferative activity for individual cell lines.

Bottom Line: Lycopene treatment for 168 consecutive hours exhibited a time-dependent and dose-dependent anti-proliferative activity against these cell lines by arresting the cell cycle at the G0 /G1 phase at physiologically achievable concentrations found in human plasma.The greatest growth inhibition was observed in MDA-MB-468 where the sub-G0 /G1 apoptotic population was significantly increased, with demonstrable cleavage of PARP.Taken together, these data indicate that the predominant anticancer activity of lycopene in MDA-MB-468 cells suggests a potential role of lycopene for the prevention of triple negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan.

Show MeSH
Related in: MedlinePlus